Author | Year | Country | Case | Disease stage | Method | Treatment | Detection | Provided information on cutoff value | Response |
---|---|---|---|---|---|---|---|---|---|
Grim[12] | 2012 | Czech Republic | 61 | locally advanced | NCT | TAC | IHC | ≥10% stained cell | Pathological CR |
Chen[13] | 2012 | China | 91 | II-IIIC | NCT | PCb | IHC | ≥10% stained cell | Pathological CR |
Petrarca[14] | 2011 | Brazil | 45 | II-III | NCT | AC-T | IHC | >5(expression score range, 0–15) | Pathological CR |
von Minckwitz[15] | 2008 | Germany | 196 | T2-3(≥3 cm) N0-2 M0 | NCT | ddAT with or without tamoxifen | IHC | >1 + (range 0-3+) | Pathological CR |
Vargas-Roig[16] | 2008 | Argentina | 110 | T2–4 N0–1 M0 | NCT | FAC/FEC or D/E | IHC | >33% of stained cells | PR + CR |
Keam[17] | 2007 | Korea, | 145 | II-III | NCT | docetaxel + doxorubicin | IHC | ≥10% stained cell | OR |
Tiezzi[18] | 2006 | Brazil | 44 | locally advanced | NCT | FEC or DE | IHC | ≥5(range 0–7) | OR |
Noguchi[19] | 2006 | Japan | 63 | NR | NR | Docetaxel | IHC | NR | OR |
Mieog[20] | 2006 | Netherlands | 107 | T1-4 | NCT | FEC | IHC | staining ≥3 indicates positive status | Pathological CR + OR |
Fernandez-Sanchez[21] | 2006 | Mexico | 40 | IIB-IIIB | NCT | FAC | IHC | ≥10% stained cell | OR |
Prisack[22] | 2005 | Germany | 517 | locally advanced | NCT | EC ± RT | IHC | score ≥100 | Pathological CR |
Kim[23] | 2005 | Japan | 63 | tumor >3Â cm and axillary lymph node involvement | NCT | docetaxel | IHC | Grades 2 and 3 | Pathologic responders |
Buchholz[24] | 2005 | USA | 82 | II-IV | NCT | FAC | IHC | presence of any cytoplasmic staining of the tumor cell cytoplasm | Pathological CR |
Pusztai[25] | 2004 | USA | 28 | IIA-IIIB | NCT | FAC | IHC | any signal in neoplastic cells | Pathological CR |
Ogston[26] | 2004 | UK | 104 | large and locally advanced | NCT | anthracycline-based ± docetaxel | IHC | ≥10% stained cell | Good pathological response |
Mathieu[27] | 2004 | France | 129 | T2 > 3 cm–T4 | NCT | AVCMF or FAC/FEC | IHC | ≥10% stained cell | Pathological CR |
Stearns[28] | 2003 | USA | 29 | T3 or T4 | NCT | A-T | IHC | Cytoplasmic staining.Intensity and % positive cells.Score ≥6 = positive | Pathological CR |
Geisler[29] | 2001 | Norway | 94 | T3/T4 and/or N2 tumors | NCT and first-line | EC | IHC | index ≥ 6 | PR |
Pernick[30] | 2000 | USA | 34 | IIB or III | NCT | adriamycin (n = 32), taxol (n = 7), or taxotere (n = 7) | IHC | 5% or more tumor cells stained. | CR |
Bottini[31] | 2000 | Italy | 157 | T2-4 N0-1 M0 | NCT | CMF ± tamoxifen or epirubicin | IHC | ≥20% stained cell | CR + OR |
Nole[32] | 1999 | Italy | 39 | T1-T3 | NCT | FLN | IHC | >10% stained cell | OR |
Colleoni[33] | 1999 | Italy | 73 | T2-T3,N0-2 | NCT | FLN or AC | IHC | >10% stained cell | OR |
Makris[34] | 1997 | UK | 90 | T1(N = 23),T2(n = 58),T3/T4(N = 9) | NCT | mitozantrone, methotrexate and tamoxifen | IHC | NR | OR |